Nature Reviews Drug Discovery Article “Advances in targeting ‘undruggable’ transcription factors with small molecules”

CEO Michael Bauer says: “Targeting the Undruggable” has been a fashionable statement or expression of ambition in recent years, however, it is now becoming a reality and a few companies successful in making the impossible dream come true. Cellestia is one of these few companies successfully working in this space, opening up access to a universe of un-exploited new targets in oncology, auto-immune and inflammatory disorders and possibly beyond”

To read the Nature Reviews Drug Discovery Article “Advances in targeting ‘undruggable’ transcription factors with small molecules” please click here.